Microarray data was deposited in the NCBI GEO database and is available under accession number GSE 78980. All other relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Bone loss due to osteoporosis (OP) is the most common cause of fractures among the elderly. Age-related OP elicits fractures with minimal trauma in up to 40% of women and 20% of men over the age of fifty and is a major health and fiscal burden \[[@pone.0160034.ref001], [@pone.0160034.ref002]\]. OP can also develop in younger individuals as a consequence of premature menopause or skeletal unloading. In the absence of gravity load on weight-bearing bones, the equilibrium between osteoblastic bone formation and osteoclastic bone resorption is uncoupled and the balance is shifted towards resorption, resulting in bone loss. Skeletal disuse can occur after prolonged bedrest on Earth but is also encountered in the weightless conditions of Space \[[@pone.0160034.ref003]\]. During orbital flight, astronauts are exposed to gravity forces below the physiological detection threshold (≤ 10^-5^*g*). Even a short-duration exposure to microgravity results in profound metabolic changes, and the lack of mechanical loading causes rapid demineralization in bones of the lower body leading to development of a disuse osteoporotic-like phenotype \[[@pone.0160034.ref004]\]. Microgravity can cause a remarkable loss of up to 2% of load-bearing bone mineral density (BMD) per month spent in Space, compared to an average 1% per year observed on Earth (starting from approximately 24--30 years of age when peak bone mass is attained) \[[@pone.0160034.ref005]\]. Microgravity-induced bone loss shows no sign of stabilization while at 0*g* and displays a highly-variable speed of skeletal recovery upon return to Earth \[[@pone.0160034.ref006]--[@pone.0160034.ref010]\]. The causes of this rapidly-progressing syndrome have not been elucidated, and only partially-effective countermeasures have been developed \[[@pone.0160034.ref011]\].

Skeletal loss has severe implications for long-time inhabitants of the International Space Station and will be a hindrance to spatial exploration since up to one half of bone mass could be lost during a three-year trip to Mars, resulting in mission-compromising fractures as well as complications from renal stones caused by skeleton-released calcium \[[@pone.0160034.ref005], [@pone.0160034.ref012]--[@pone.0160034.ref014]\]. The mechanosensors which control bone loss during unloading are not known, and the striking difference in microgravity-induced mineral loss between bone derived from endochondral formation (eg. trabecular bone) and bone derived from membraneous formation (calvarial bone) has also not been fully analysed. Elucidation of the causes of skeletal loss at 0*g* is further complicated by the fact that the two main cellular components regulating bone turnover, the osteoblasts and osteoclasts, are differently affected by microgravity. Osteoblasts exposed to 0*g* undergo decreases in cellular integrity with modified microtubule structure, focal adhesions and increasingly fragmented nuclei, while osteoclasts present higher numbers of discrete resorption pits and increased cellular activity \[[@pone.0160034.ref015]\]. Spaceflight countermeasures to bone loss include exercise and resistive training, artificial musculoskeletal loading, electrical stimulation and vibration treatment, as well as dietary additions of vitamin D, K, calcium and various drugs \[[@pone.0160034.ref016]\]. While physical activity in Space helps to counter muscle atrophy, it does not prevent bone loss and none of these measures fully compensate for skeletal degradation \[[@pone.0160034.ref010], [@pone.0160034.ref013], [@pone.0160034.ref014]\]. In long-duration bedrest studies which mimic microgravity's physiological effects, treatment of male subjects with the anti-resorptive bisphosphonate drugs alendronate or pamidronate (osteoclast inhibitors) prevented some, but not all, bone loss \[[@pone.0160034.ref017], [@pone.0160034.ref018]\]. Furthermore, skeletal bone formed during bisphosphonate administration does not display the mechanical integrity of normal bone \[[@pone.0160034.ref006], [@pone.0160034.ref019]\] and high doses of anti-resorptive drugs may inhibit formation in unloaded bone \[[@pone.0160034.ref020]\]. Consequently, an alternative to be investigated is the use of anabolic substances such as parathyroid hormone (PTH) and parathyroid hormone-related hormone (PTHrP) which promote bone formation rather than inhibit resorption \[[@pone.0160034.ref021], [@pone.0160034.ref022]\].

PTHrP is a secreted factor expressed in almost all normal fetal and adult tissues. It acts as an autocrine, paracrine or intracrine factor in a wide range of developmental and physiological processes, including skeletal development and growth \[[@pone.0160034.ref023], [@pone.0160034.ref024]\]. The 13 N-terminal amino acids of PTHrP are highly-homologous to those of PTH, a characteristic that allows PTHrP to activate their common type 1 PTH/PTHrP receptor. PTH and PTHrP differ in the remainder of their sequence, a fact which accounts at least in part for the distinct properties of the two molecules \[[@pone.0160034.ref023], [@pone.0160034.ref024]\]. The major role played by PTHrP in bone development was made evident through *Pthrp* gene deletion which caused profound abnormalities in the development of the cartilaginous growth plate \[[@pone.0160034.ref025], [@pone.0160034.ref026]\], a phenotype not seen in mice with *PTH* deletion \[[@pone.0160034.ref027]\]. Heterozygous mice with only one null *Pthrp* allele (*Pthrp* ^*+/-*^) developed premature OP due to decreased bone formation linked to enhanced apoptosis of osteogenic cells \[[@pone.0160034.ref028]\]. Knock-out mice with a selective *Pthrp* deletion targeting only the osteoblasts further recapitulated this severe osteoporotic phenotype and importantly, exogenous application of PTH or PTHrP prevented apoptosis and associated bone loss \[[@pone.0160034.ref029]\]. PTH~1-34~ (teriparatide, Forteo^™^) is currently the only approved anabolic drug for treatment of osteoporosis but may cause bone resorption, hypercalcemia, nausea, muscle cramps and other adverse side-effects. In contrast, a study conducted on post-menopausal women showed that the ~1--36~ N-terminal peptide of PTHrP did not activate bone resorption (based on bone marker responses, although changes in BMD were not measured) and acted as a pure anabolic agent while causing none of the adverse effects observed with teriparatide \[[@pone.0160034.ref030]\]. Although intermittent treatment with PTHrP causes an anabolic response, continuous treatment causes paradoxical downregulation of osteogenic genes resulting in skeletal catabolism \[[@pone.0160034.ref031], [@pone.0160034.ref032]\].

Decreased expression levels of PTHrP have been reported in rat long bones and cultured osteoblasts following exposure to microgravity \[[@pone.0160034.ref033]\], and loss of PTHrP may underlie at least part of the pathophysiology of microgravity-induced OP. We consequently tested the hypothesis that PTHrP could counter actual or simulated microgravity-induced deleterious effects in osteoblasts, and we investigated a timeline of viability for osteoblasts in weightlessness which would predispose astronauts to impaired bone formation. We also examined the efficacy of exogenous PTHrP~1-36~ peptide administration in preventing osteoblast viability loss in microgravity conditions. For these studies, we used trabecular and calvarial osteoblasts isolated one day before birth from bones of *Pthrp* ^+/+^, ^+/-^, or ^-/-^ mice. The cells in adherent conditions were subjected to Spaceflight aboard the Foton M3 satellite or to simulated microgravity in a Synthecon rotary cell culture system (RCCS) for 6-day experiments, with or without intermittent PTHrP ~1--36~ treatment. We observed that PTHrP expression confers resistance to microgravity-induced cell death, that a very large proportion of the genes affected by microgravity is common to those affected by *Pthrp* gene deletion, and that intermittent treatment with the PTHrP~1-36~ peptide reverses the 0*g* effects on TO viability.

Materials and Methods {#sec002}
=====================

Animal Ethics Statement {#sec003}
-----------------------

All experiments were carried out in compliance with regulations of the McGill University Institutional Animal Care Committee (Animal permit: 5210) which specifically approved this study.

The mice were housed in conventional (non-barrier) animal facilities at 21°C with light-dark cycles of 12 hours, and were fed Bacon Softies^™^ soft pellets (Bio Serv) and water from drinking bottles *ad libitum*.

Animals {#sec004}
-------

Mice with various levels of *Pthrp* gene ablation (wild-type *Pthrp* ^+/+^, heterozygous *Pthrp* ^+/-^, and homozygous *Pthrp* ^-/-^) in a C57BL/6 background \[[@pone.0160034.ref026]\] were used to obtain osteoblasts. Because homozygous animals (*Pthrp* ^-/-^) exhibit perinatal lethality due to skeletal and pulmonary problems \[[@pone.0160034.ref026]\], osteoblasts were collected from fetal mice of all types one day before birth. Briefly, *Pthrp* ^+/-^ males were bred with *Pthrp* ^+/-^ females, pregnant females were sacrificed by cervical dislocation one day before partum and the fetal mice collected and sacrificed by decapitation. The animals were immediately surface-sterilized in 70% ethanol, tail samples were preserved for genotyping, and femoral and cranium bones extracted immediately to obtain trabecular and calvarial osteoblast cells respectively.

Preparation of osteoblasts and cell culture {#sec005}
-------------------------------------------

The trabecular and calvarial cells were obtained by a method modified after \[[@pone.0160034.ref034]\]. Briefly, calvarial (cranium, derived from membraneous bone formation) and trabecular (femur, derived from endochondral bone formation) bones were dissected from the animals and predigested in 6-well culture plates for 15 min at 37°C with gentle rotation in digestion medium (TCDA) made immediately before use: trypsin 0.05%, type I collagenase (2 mg/ml, Gibco), DNAse I (0.3 mg/ml, Sigma), penicillin streptomycin (100 U/ml). Bones were transferred to new 6-well plates with fresh TCDA, chopped into small slivers, particles were transferred to a third plate with TCDA and incubated at 37°C 15 min with rotation. Finally, the bone fragments were transferred to a fourth plate containing MAF medium (α-MEM with 15% FBS, penicillin/streptomycin 100 U/ml, fungizone 0.25 ug/ml) and incubated without rotation at 37°C in a humidified cell incubator (5% CO~2~). Only the cells emerging from the bone fragments at this step were kept for experimental purposes. The MAF medium was changed every two days and cells were transferred to 6-well plates when confluent. Aliquots were incubated with AGD differenciation medium (α-MEM 15% FBS, penicillin/streptomycin 100U/ml, fungizone 0.25 ug/ml, ascorbic acid 50 ug/ml, glycerophosphate 10 mM and dexamethasone 0,1 uM final) \[[@pone.0160034.ref035]\] or MAF as control to test for differenciation markers. The osteoblast primary cultures were filtered through sterile nylon cell strainers (100 microns, BD Biosciences), passaged twice, and 500,000 cells (minimum) were frozen per vial in 90% FBS, 10% DMSO using cryojars (ethanol/ dry ice) for 4 hours at -80°C. The cell vials were transferred to liquid nitrogen storage after 2 days. All culture reagents were from Wisent.

Genotyping {#sec006}
----------

Tail segments were incubated in lysis buffer (100 mM Tris-HCl 8.0, 5 mM EDTA 8.0, 0.2% SDS, 200 mM NaCl, 0.2 mg/ml proteinase K) at 55°C for 16 hours. Genomic DNA was extracted with phenol/CHCl~3~, ethanol-precipitated and resuspended in TE buffer. Aliquots were digested with PvuII, separated by agarose electrophoresis, and blots hybridized with a PTHrP-specific probe \[[@pone.0160034.ref026]\].

Culture for Space mission bioreactors {#sec007}
-------------------------------------

The available surface on culture slides in the Foton M3 mission biomodules was extremely limited, and allowed testing of the *Pthrp* ^+/+^ and ^-/-^ genotypes only. Cultured primary osteoblasts of both genotypes from calvarial and trabecular origin were exposed to AGD differenciation medium for 4--5 days then trypsinised, counted and cells were attached at very high density (25,000 cells/cm^2^, or 6,500 cells/compartment in 4-compartment slides) to the growth surfaces of sterile CC2 glass slides (Nunc). These slides were handled in a completely sterile fashion and placed inside 10cm culture dishes in a normal culture incubator (5% CO~2~) for a 4-day pre-attachment period in AGD medium. The CC2 slides superstructures were removed under sterile conditions, the glass slides inserted into the sterile mission biomodules and connected to the feeding syringes and waste exhaust lines of the automated experimental trays ([Fig 1A](#pone.0160034.g001){ref-type="fig"}, CALM Technologies, Kingston, Canada). Two identical trays were sealed and powered by battery to maintain 37°C temperature and provide medium changes every 48 hours. One tray was kept at 1*g* at the European Space Research and Technology Centre (ESTEC, Noordwijk, The Netherlands) while the twin tray (for 0*g*) was transported over a period of 4 days to Baikonour and installed aboard the Roscosmos (Russian Federal Space Agency) Foton M3 satellite which was launched into orbital flight. (<http://esamultimedia.esa.int/docs/foton/FOTON-M3_brochure.pdf>).

![Endogenous PTHrP protects trabecular osteoblasts from Space microgravity-induced apoptosis. (6-day experiments).\
**(A)** Automated flight-ready tray for conducting cell culture experiments aboard Foton M3 satellite. Osteoblasts were attached onto CC2 culture slides inside three bioreactors (lower right) in a sealed pathway. **(B)** Proportion of apoptotic cells in trabecular osteoblasts in bioreactors after 6 days in Space microgravity (0*g*) or in normal Earth gravity (1*g*). \*\* p \< 0.01. White bars: untreated; black bars: 2-h daily treatment with PTHrP~1-36~ 10^-8^M. **(C)** Proportion of apoptotic cells in calvarial osteoblasts in bioreactors after 6 days in Space microgravity (0*g*) or in normal Earth gravity (1*g*). No PTHrP~1-36~ treatment was conducted on calvarial cells. Scale bar A: 15 cm.](pone.0160034.g001){#pone.0160034.g001}

Experimental flight conditions {#sec008}
------------------------------

Experimental conditions were automatically started one day after reaching orbital flight. Cells were fed fresh AGD growth medium every day, or received a daily 2-hour treatment with 10^-8^M PTHrP peptide amino acids 1--36, (Bachem, Germany) in AGD, followed by a phosphate-buffered saline (PBS) rinse, then fresh AGD medium. Intermittent PTHrP~1-36~ treatment was used as it provides anabolic effects on bone whereas continuous treatment does not \[[@pone.0160034.ref036]\]. After 6 days of experimentation, the cells were fixed with 1% glutaraldehyde *in situ* on the slides within the 3 bioreactors, then stored in PBS at 15°C. After retrieval from the satellite, slides were stored in PBS at 4°C until assays. Experimental conditions were identical for both 0*g* and 1*g* trays (described in [S1 Table](#pone.0160034.s002){ref-type="supplementary-material"}).

Apoptosis assay {#sec009}
---------------

Mission slides were analysed for apoptosis events using the single-stranded DNA (ssDNA) detection technique \[[@pone.0160034.ref037]\]. The glass slides with glutaraldehyde-fixed cells were heated for 20 minutes at 75°C in neat formamide, rinsed with H~2~O, blocked with 3% non-fat dry milk for 1h at room temperature, reacted with a monoclonal antibody to ssDNA (1:10) coupled with horseradish peroxidase (Chemicon), then colored with freshly-prepared diaminobenzidine (DAB) and counter-stained with hematoxylin. Fixed cells positive for DAB (i.e.ssDNA) were apoptotic at the time of in-flight fixation, cells stained with hematoxylin were viable at the same moment. 11 optical fields were counted on each slide and the proportion of apoptotic cells to non-apoptotic cells at the time of fixation was determined.

Simulated microgravity in rotary cell culture system {#sec010}
----------------------------------------------------

The flight data was completed, confirmed and expanded using the Synthecon Revolving Cell Culture System (RCCS) Earth-based microgravity simulator consisting of a horizontally-rotating axis connected to a sterile 10-ml disposable growth chamber called High Aspect Ratio Vessel (HARV) with a CO~2~-permeable membrane ([Fig 2A](#pone.0160034.g002){ref-type="fig"}, Synthecon, Houston, TX). The equipment was used inside a standard CO~2~ incubator while connected to an external speed regulator and power supply. Because free, non-adherent cells would rapidly undergo anoikis-induced apoptosis \[[@pone.0160034.ref038]\], osteoblasts grown in AGD medium were trypsinised, counted, and aliquots of 10^6^ cells were pre-attached to sterile MicroHex microcarriers (Nunc) using 1 ml of 50 cm^2^/ml MicroHex per 10^6^ cells, and incubated 4 days in AGD medium at 30°C in culture plates coated with sterile 4% agarose (Gibco) to prevent attachment \[[@pone.0160034.ref039]\]. The medium was changed every second day. Primary osteoblasts attach to the surface of the microcarriers and develop in a manner similar to osteoblasts plated on standard culture plasticware except for the fact that the cells create three-dimensional connections with more than one plastic surface, resulting in microcarrier-cell aggregates ([Fig 2B and 2C](#pone.0160034.g002){ref-type="fig"}). Within 24 hours of attachment at 1*g*, the cell/microcarrier structures assembled into clumps visible to the naked eye which mimicked the more natural cellular environment found in a living organism. After 5 days, MicroHex-attached osteoblasts (5 x 10^6^) were transferred to 10-ml sterile Synthecon HARV chambers containing AGD medium which were placed inside a standard cell incubator (37°C, 5% CO~2~). The units were rotated at optimized speed (20 rpm) to maintain the constant free fall state characteristic of orbital flight and which is the cause of weightlessness. The rotation simulated 0*g* while avoiding shear forces due to excessive rotation and collision with vessel walls. Two chambers were rotated simultaneously on the same rotation axis, one containing the untreated control receiving daily medium change, the other receiving a daily 2-h PTHrP~1-36~ 10^-8^M treatment followed by fresh medium. Cells on microcarriers but growing in AGD medium in agarose-coated plasticware in a standard cell culture incubator were used as 1g controls and received the same regimen of treatments or medium changes. Triplicate experiments were conducted with conditions identical to those aboard the satellite. At the end of the 6^th^ day, cells were collected, trypsinized to release them from the microcarriers, and aliquots analysed for viability by Trypan Blue analysis. Treatment and media change conditions for 6-week experiments were identical to those lasting 6 days.

![Allelic effect of endogenous PTHrP levels in simulated microgravity, and compensation by exogenous PTHrP ~1--36~ (6-day experiments).\
**(A)** Microgravity simulation apparatus (RCCS) with one rotating culture unit (HARV). **(B)** MicroHex carriers with attached trabecular osteoblasts in culture. **(C)** Cell-induced MicroHex aggregate in culture (occurs for both trabecular and calvarial osteoblasts). **(D)** Trabecular osteoblast viability after 6 days on MicroHex carriers in normal gravity (1*g*) or in simulated microgravity (0*g*) (triplicate 6-day experiments). White bars: untreated; black bars: 2-h daily treatment with PTHrP~1-36~ 10^-8^M. \*\* p \< 0.01, \*\*\* p \< 0.001. Scale bars: B, C: 200 μm.](pone.0160034.g002){#pone.0160034.g002}

Trypan Blue viability test {#sec011}
--------------------------

During long-term experiments, sampling from the HARV rotating chamber was conducted at weekly intervals. Aliquots of cell-microcarriers aggregate were quickly collected in sterile fashion from the momentarily-immobilised HARV, and transferred to sterile microfuge tubes. The aggregates were washed with growth medium then trypsinized in tubes kept horizontally for 20 minutes at 37°C. After cell detachment, the tubes were put vertically in racks to sediment the microcarriers, and the supernatant collected. Microcarriers were rinsed twice with growth medium to collect residual cells, the trypsinised combined volumes were centrifuged, the cells resuspended in growth medium and stained with Trypan Blue for viability \[[@pone.0160034.ref040]\].

RNA extraction and microarrays {#sec012}
------------------------------

Collected cells from duplicate experiments were lysed on MicroHex microcarriers using Trizol (InVitrogen, Carlsbad, CA) according to manufacturer's intructions, frozen at -80°C and sent for RNA extraction and microarray analysis to the Centre d'Innovation de Génome Québec, (Montréal, QC). Illumina Mouse Ref-8 v2.0 slides (25,697 probes) were hybridized with trabecular osteoblast samples (*Pthrp* ^+/+^ and *Pthrp* ^-/-^) from experiments in 1*g* or in simulated microgravity for 6 days, conducted with or without intermittent (2-h daily) PTHrP ~1--36~ treatment (8 different conditions in total). Data pre-processing and analysis of expressions levels results were conducted using the FlexArray software version 1.5 from Génome Québec \[[@pone.0160034.ref041]\] <http://genomequebec.mcgill.ca/FlexArray>. Normalization was performed with the Lumi package and the data were analyzed using EB Wright and Simon statistical analysis. We retained only gene lists with probe values of p ≤ 0.05 for analysis. Cluster analysis was performed with the Database for Annotation, Visualization and Integrated Discovery online functional annotation tool \[[@pone.0160034.ref042]\] and by manual searches. Venn diagrams were made using FunRich analysis tool \[[@pone.0160034.ref043]\]. Microarray data was deposited in the NCBI GEO database and is available under accession number GSE 78980.

Analysis software, statistics {#sec013}
-----------------------------

Statistical analyses of viability experiments were conducted using GraphPad Prism 4.0 for Windows (GraphPad Software, San Diego, CA), using one-way ANOVA with Bonferroni's multiple comparison post-test. Results were considered significant at p ≤ 0.05.

Results {#sec014}
=======

Endogenous PTHrP and exogenous PTHrP~1-36~ protect trabecular osteoblasts from Space microgravity-induced apoptosis {#sec015}
-------------------------------------------------------------------------------------------------------------------

In order to investigate the role of PTHrP in bone cells exposed to space microgravity, trabecular and calvarial osteoblasts obtained from bones of *Pthrp* ^-/-^ fetal mice and *Pthrp* ^+/+^ littermates \[[@pone.0160034.ref026]\] were attached to CC2 culture slides and inserted into sterile bioreactors connected online to the automated experimental trays ([Fig 1A](#pone.0160034.g001){ref-type="fig"}). The 6-day experiment involved a daily 2-hour treatment with 10^-8^ M PTHrP ~1--36~ peptide, or a control with growth medium change only for both the 0*g* and 1*g* trays ([S1 Table](#pone.0160034.s002){ref-type="supplementary-material"}). After return to Earth, an analysis of apoptotic cells was conducted by the ssDNA method \[[@pone.0160034.ref037]\]. A comparison of *Pthrp* ^+/+^ TOs in the 1*g* tray with equivalent cells aboard the Foton3 satellite indicates that a 6-day exposure to microgravity causes no significant induction of apoptosis. For *Pthrp* ^*-/-*^ TOs, however, a 20.4 ± 5.0% increase in apoptotic cells was observed at 0*g* over the 6-day period compared to the equivalent *Pthrp* ^-/-^ cells which had remained on Earth ([Fig 1B](#pone.0160034.g001){ref-type="fig"} white bars). Intermittent treatment with 10^-8^M PTHrP ~1--36~ peptide reduced the number of apoptotic cells in 0g compared to 1g by 11.6 ± 4.1% and 50.2% ± 5.4% for ^+/+^ and ^-/-^ TOs respectively ([Fig 1B](#pone.0160034.g001){ref-type="fig"} black bars) (p \< 0.01). In contrast, over the 6-day period, osteoblasts of calvarial origin (COs) showed little difference in apoptosis due to microgravity exposure although *Pthrp* ^*-/-*^ COs displayed elevated apotosis proportions compared to ^+/+^ COs regardless of gravity conditions ([Fig 1C](#pone.0160034.g001){ref-type="fig"}). COs were not treated with PTHrP due to the limited reaction volumes available within the experimental trays. These data implicate PTHrP in TO survival in short-term microgravity exposure, and show that in the absence of endogenous PTHrP, intermittent treatment with exogenous PTHrP ~1--36~ reduces the number of cells undergoing apoptosis.

Allelic effect of endogenous PTHrP levels in simulated microgravity, and compensation by exogenous PTHrP ~1--36~ {#sec016}
----------------------------------------------------------------------------------------------------------------

In order to reproduce and expand Space flight results on the role of endogenous and exogenous PTHrP in trabecular octeoblasts, we used the Revolving Cell Culture System Earth-based microgravity simulator from Synthecon ([Fig 2A](#pone.0160034.g002){ref-type="fig"}). TOs from *Pthrp* ^+/+^, *Pthrp* ^+/-^ and *Pthrp* ^-/-^ fetal animals attached to sterile MicroHex microcarriers ([Fig 2B](#pone.0160034.g002){ref-type="fig"}) spontaneously transformed into three-dimensional structures within 24 h ([Fig 2C](#pone.0160034.g002){ref-type="fig"}) and these aggregates remained intact throughout the experiment. The low negative impact of our design is evident in the excellent survival of various types of osteoblasts in the Synthecon chambers for extended periods of time (see next section).

Cell-microcarrier aggregates were collected after 6 days, trypsinised and analysed by Trypan blue for viability. After 6 days, *Pthrp*^+/+^ TOs presented a low (7.5±1.1%) percentage of non-viable cells in both 0*g* and 1*g* experimental set-ups. Heterozygous *Pthrp* ^+/-^ TOs displayed a higher percentage of non-viable cells (22% ± 2.1 at 0*g* compared to 13.5±1.9% at 1*g*) p \< 0.01, and *Pthrp* ^-/-^ TOs were greatly affected by weightlessness (non-viable cells: 43±3.1% at 0*g* compared to 20 ± 2.5% at 1*g*) ([Fig 2D](#pone.0160034.g002){ref-type="fig"} white bars) p \< 0.001. Intermittent treatment with PTHrP ~1--36~ made little difference at 1*g* or 0*g* for *Pthrp*^+/+^ TOs but reduced the percentage of non-viable cells from 22.1 to 12.7 ± 4% at 0*g* in the heterozygous TOs. In *Pthrp* ^-/-^ cells, PTHrP ~1--36~ intermittent treatment decreased non-viable cells from 20±3.2% to 11±2.5% at 1*g*, but there was a striking reduction (43±4.2% to 11±5.0%) in numbers of non-viable cells at 0*g* ([Fig 2D](#pone.0160034.g002){ref-type="fig"} black bars) p \< 0.001. These data confirm the results obtained in Space: there is little to no effect of microgravity on *Pthrp*^*+/+*^ cell viability in 0g over 6 days, but incremental loss of viability as *Pthrp* levels of expression decrease. Intermittent PTHrP~1-36~ maintains or increases viability, especially in *Pthrp*^*-/-*^ TOs. The simulated microgravity experiments demonstrate again the greater vulnerability of *Pthrp*-ablated trabecular osteoblasts to microgravity and point to a definite allelic effect for *Pthrp* ablation.

Long-term exposure to simulated microgravity is detrimental to wild-type trabecular osteoblasts but compensated for by exogenous PTHrP~1-36~ treatment {#sec017}
------------------------------------------------------------------------------------------------------------------------------------------------------

In order to investigate the effect of longer microgravity exposure on wild-type TOs, 6-week experiments were conducted with wild-type *Pthrp*^+/+^ TO cells attached to microcarriers and exposed to RCCS-simulated microgravity (0*g*) or to normal gravity (1*g*). Incubation conditions, media changes and intermittent daily PTHrP ~1--36~ treatments (10^-8^ M) were identical to those described above. Samples of osteoblast aggregates on microcarriers were drawn from 1*g* and 0*g* experimental set at weekly intervals, trypsinized, and cell viability assessed by Trypan blue staining. The three-dimensional cell aggregates on micro-carriers provide *in vitro* growth conditions that are closer to those found *in vivo* compared to single layer cultures \[[@pone.0160034.ref044]\] and allow excellent survival of wild-type trabecular osteoblasts in normal gravity over the course of 6 weeks; wild-type *Pthrp*^+/+^ TOs attached to MicroHex carriers easily survived 6 weeks in culture plates in normal 1*g* gravity, with only a 10--15% overall loss in viability ([Fig 3](#pone.0160034.g003){ref-type="fig"}). In contrast, *Pthrp*^+/+^ TOs on MicroHex carriers exposed to simulated microgravity (0*g*) started to lose viability after 2 weeks and presented a striking 50% non-viable cells after 6 weeks. Importantly, a 2-h daily treatment with PTHrP~1-36~ over the 6-week period reduced this loss of viability to 15%, similar to that of cells left at 1*g*. As expected from results observed in [Fig 2](#pone.0160034.g002){ref-type="fig"}, *Pthrp*^*-/-*^ TOs did not survive past week 2 (not shown). These results suggest that microgravity-induced molecular events leading to cell death occur early in wild-type TOs and that intermittent treatment with PTHrP ~1--36~ peptide maintains viability in these cells over the course of 6 weeks.

![Long-term exposure to simulated microgravity is detrimental to wild-type trabecular osteoblasts but compensated for by exogenous intermittent PTHrP~1-36~ treatment.\
*Pthrp*^*+/+*^ trabecular osteoblasts at 1*g* (■) or 0*g* (▼). *Pthrp*^*+/+*^ trabecular osteoblasts treated with PTHrP~1-36~ 10^-8^M.at 1*g* (▲) or 0*g* (♦). (triplicate 6-week experiments). Viability estimated by Trypan blue. \*\* p \< 0.01, \*\*\* p \< 0.001.](pone.0160034.g003){#pone.0160034.g003}

Long-term exposure to simulated microgravity has little negative effect on calvarial osteoblasts {#sec018}
------------------------------------------------------------------------------------------------

Long-term experiments (6-weeks) were conducted in the RCCS equipment with calvarial osteoblasts from *Pthrp* ^+/+^ and ^-/-^ mice. CO cells attached to MicroHex carriers produced three-dimensional structures similar to those observed in trabecular experiments. Experimental 0*g* and 1*g* conditions were identical to above except that no exogenous PTHrP ~1--36~ treatment was conducted. [Fig 4](#pone.0160034.g004){ref-type="fig"} shows that COs from wild type *Pthrp* ^+/+^ mice maintain comparable viability in 0*g* and 1*g* for at least 6 weeks (10 to 12% non-viable cells). As suggested by results from [Fig 1C](#pone.0160034.g001){ref-type="fig"}, *Pthrp* ^-/-^ COs are more sensitive to 0g but the percentage of non-viable cells after 6 weeks at 0*g* is only 13% above that of *Pthrp* ^-/-^ calvarial cells at 1*g*. These results indicate that wild-type COs are little affected by a 6-week exposure to microgravity, but that PTHrP nevertheless plays some role in resistance to weightlessness in cranium-derived osteoblasts since *Pthrp* ^-/-^ calvarial cells slowly lose viability in 0*g*.

![Long-term exposure to simulated microgravity has little negative effect on calvarial osteoblasts.\
*Phtrp*^*+/+*^ calvarial osteoblasts at 1g (▼) or 0g (■). *Pthrp*^*-/-*^ calvarial osteoblasts at 1g (●) or 0g (▲). (triplicate 6-week experiments). No exogenous PTHrP~1-36~ treatment was applied in this experiment. Viability estimated by Trypan blue. \* p \< 0.05, \*\* p \< 0.01.](pone.0160034.g004){#pone.0160034.g004}

Microarray analysis conducted on trabecular osteoblasts: effect of 6-day exposure to microgravity, effect of *Pthrp* ablation, and reversal by intermittent PTHrP ~1--36~ treatment {#sec019}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Microgravity-induced adverse effects appear early on in TOs exposed to weightless conditions. Since these early events are crucial to all subsequent physiological changes, expression microarrays after 6 days at 0*g* were analysed in order to identify the genes involved. Microarray analysis (Illumina Mouse Ref8) was conducted on *Pthrp*^+/+^ wild type TOs exposed to 6 days of simulated microgravity to check for early gene expression changes that lead to microgravity-induced alterations detectable in the following weeks. 0*g*-induced changes in *Pthrp*^*+/+*^ TOs were also compared with those resulting from *Pthrp* gene ablation. Reversal was examined upon intermittent treatment with the PTHrP~1-36~ peptide (10^-8^M) of *Pthrp*-ablated and 0*g*-exposed TO cells.

In *Pthrp*^+/+^ trabecular osteoblasts, a 6-day period in simulated microgravity significantly upregulated 59 genes (fold change \> 2.0, *p* \< 0.05, complete gene list in [S2A Table](#pone.0160034.s003){ref-type="supplementary-material"}), and downregulated 129 genes (fold change \< 0.5, *p* \< 0.05, complete gene list in [S2B Table](#pone.0160034.s003){ref-type="supplementary-material"}) compared to *Pthrp*^+/+^ TOs which remained at 1*g* (total number of genes significantly affected by 6 days at 0g = 188). *Pthrp* gene ablation (i.e. comparison of *Pthrp*^+/+^ and *Pthrp*^-/-^ TOs at 1*g*) significantly upregulated 270 genes (fold change \> 2.0, *p* \< 0.05, complete genelist in [S3A Table](#pone.0160034.s004){ref-type="supplementary-material"}) and downregulated 493 genes (fold change \< 0.5, *p* \< 0.05, complete gene list in [S3B Table](#pone.0160034.s004){ref-type="supplementary-material"})(total number of genes significantly affected by *Pthrp* ablation = 763).

With this information, a parallel was established between the effects of microgravity exposure on wild-type *Pthrp*^+/+^ TOs, and the changes in gene expression occurring after *Pthrp* ablation at 1*g*. 52 upregulated and 115 downregulated genes were found to be common between 0*g* exposure and *Pthrp* ablation effects ([Fig 5A and 5B](#pone.0160034.g005){ref-type="fig"}, intersects, complete list of common genes in Tables [1](#pone.0160034.t001){ref-type="table"} and [2](#pone.0160034.t002){ref-type="table"}). In all, 88% of the genes modified by microgravity were similarly affected by *Pthrp* ablation. Clustering analysis suggests the common genes are mainly related to the following metabolic categories: prolactins ([up]{.ul}: *Plf2*, *Mrpplf3)*, genes involved in bone growth, mineralization and bone morphogenic protein (BMP) metabolism ([up]{.ul}: *Aqp5; Grem1*, *Inhba*, *Nbl1*, *Cryab*, *Ank*, *CD44*, *Scx*, *Mustn1*, *Tnfrsf11b* (osteoprotegerin), *Bdnf*, *Stmn2*; [down]{.ul}: *Ptn* (pleiotrophin), *Hp*, *Scara5*, *Itm2a*, *Ptn*, *Dlk1*, *Ramp2*, *Dab*, *Eno1*, *CD14*, *Hemp1*, *Lgmn*, *Txnip*, *Ptx3)*, apoptosis/survival ([down]{.ul}: *Clu*, *Rbm3*), extracellular matrix components ([up]{.ul}: *Timp3*, *Prelp*, *Ctgf*, *Col7a1*; [down]{.ul}: *Lum*, *Dcn*, *H19*, *Nid2*, *Col3a1*, *Dpt*, *Ctsc*), Wnt signaling ([up]{.ul}: *Gpc1*, *Nkd2*; [down]{.ul}: *Sfrp 2* and *1*), IGF signaling ([down]{.ul}: *Igfbp5* and *3*, *Igf2*), heat-shock proteins ([up]{.ul}: *Hspb1* and *8*), chemokines ([down]{.ul}: *Cxcl12* and *4*, *Ccr5*), cell cycle control ([up]{.ul}: *Ccng1*, [down]{.ul}: *Cdkn1c*), as well as a variety of histone genes. Importantly, none of the significantly-affected genes presented a contradictory direction change in expression level between *Pthrp* ablation or microgravity treatment.

![Venn diagrams illustrating the number of trabecular osteoblast genes significantly up- or downregulated by microgravity exposure (6 days) or by *Pthrp* ablation, and reversed by PTHrP~1-36~ treatment.\
**(A)** 52 genes are upregulated by both 0g (yellow) and *Pthrp* ablation (blue). Fold change \> 2.0, *p* \< 0.05. **(B)** 115 genes are downregulated by both 0*g* (yellow) and *Pthrp* ablation (blue). Fold change \< 0.5, *p* \< 0.05. **(C)** 24 genes are upregulated by both 0g (yellow) and *Pthrp* ablation (blue), and are also downregulated (central intersect) by PTHrP~1-36~ treatment (red). Fold change \< 0.65, *p* \< 0.05. **(D)** 50 genes are downregulated by both 0*g* (yellow) and *Pthrp* ablation (blue), and upregulated (central intersect) by PTHrP~1-36~ treatment (red). Fold change \>1.5, *p* \< 0.05.](pone.0160034.g005){#pone.0160034.g005}

10.1371/journal.pone.0160034.t001

###### Genes (52) upregulated by both microgravity and *Pthrp* ablation.

![](pone.0160034.t001){#pone.0160034.t001g}

  Target ID       Definition (all probes: *Mus musculus*)                                                       RefSeq ID                   Fold change 0g     Fold change ablation   C
  --------------- --------------------------------------------------------------------------------------------- --------------------------- ------------------ ---------------------- ----
  PLF2            prolactin family 2, subfamily c, member 3 (Prl2c3), mRNA.                                     NM_011118.1                 12.81098           20.67081               P
  MRPPLF3         prolactin family 2, subfamily c, member 4 (Prl2c4), mRNA.                                     NM_011954.2                 11.76853           19.04649               P
  AQP5            aquaporin 5 (Aqp5), mRNA.PREDICTED: similar to aquaporin 5 (LOC100046616), mRNA.              NM_009701.4XM_001476512.1   7.7909763.627969   25.586929.547247       A
  GREM1           gremlin1 (Grem1) mRNA.                                                                        NM_011824.1                 4.151464           5.17375                B
  GPC1            glypican 1 (Gpc1), mRNA.                                                                      NM_016696.3                 4.13393            4.008327               W
  ALDH3A1         aldehyde dehydrogenase family 3, subfamily A1 (Aldh3a1), mRNA.                                NM_007436.1                 3.821048           2.733907               
  ASS1            argininosuccinate synthetase 1 (Ass1), mRNA.                                                  NM_007494.3                 3.663361           2.781254               
  NKD2            naked cuticle 2 homolog (Drosophila) (Nkd2), mRNA.                                            NM_028186.3                 3.63063            9.964373               W
  NQO1            NAD(P)H dehydrogenase, quinone 1 (Nqo1), mRNA.                                                NM_008706.4                 3.439677           9.410905               
  INHBA           inhibin beta-A (Inhba), mRNA.                                                                 NM_008380.1                 3.374437           6.03861                B
  HIST1H4H        histone cluster 1, H4h (Hist1h4h), mRNA.                                                      NM_153173.2                 3.122563           6.525515               H
  HSPB1           heat shock protein 1 (Hspb1), mRNA.                                                           NM_013560.1                 2.937195           3.686913               HS
  CRIP2           cysteine rich protein 2 (Crip2), mRNA.                                                        NM_024223.1                 2.87678            4.260978               
  TIMP3           tissue inhibitor of metalloproteinase 3 (Timp3), mRNA                                         NM_011595.2NM_011595.2      2.8337662.168426   4.7180244.573879       E
  ESD             esterase D/formylglutathione hydrolase (Esd), mRNA.                                           NM_016903.2                 2.617979           4.782361               
  PRELP           proline arginine-rich end leucine-rich repeat (Prelp), mRNA.                                  NM_054077.3                 2.563206           2.682429               E
  1110032E23RIK   RIKEN cDNA 1110032E23 gene (1110032E23Rik), mRNA                                              NM_133187.2                 2.532211           5.501027               
  GDF15           growth differentiation factor 15 (Gdf15), mRNA.                                               NM_011819.1                 2.506674           2.841855               T
  AHRR            aryl-hydrocarbon receptor repressor (Ahrr), mRNA.                                             NM_009644.2                 2.366026           2.51242                
  NBL1            neuroblastoma, suppression of tumorigenicity 1 (Nbl1), mRNA.                                  NM_008675.1                 2.362421           2.214473               B
  CRYAB           crystallin, alpha B (Cryab), mRNA.                                                            NM_009964.1                 2.332638           5.135748               B
  FABP3           fatty acid binding protein 3, muscle and heart (Fabp3), mRNA.                                 NM_010174.1                 2.32906            7.70136                
  MDM2            transformed mouse 3T3 cell double minute 2 (Mdm2), mRNA.                                      NM_010786.2NM_010786.3      2.318342.246531    2.8090142.71183        
  KCTD10          potassium channel tetramerisation domain containing 10 (Kctd10), mRNA.                        NM_026145.3                 2.279135           2.72172                IC
  SGK             serum/glucocorticoid regulated kinase 1 (Sgk1), mRNA.                                         NM_011361.1                 2.240079           2.362139               
  ANK             progressive ankylosis (Ank), mRNA.                                                            NM_020332.3                 2.228785           9.115022               B
  EPHX1           epoxide hydrolase 1, microsomal (Ephx1), mRNA.                                                NM_010145.2                 2.215451           2.907278               
  WHRN            whirlin (Whrn), transcript variant 3, mRNA.                                                   NM_001008792.1              2.202689           2.327795               
  CD44            CD44 antigen (Cd44), transcript variant 2, mRNA.                                              NM_001039150.1              2.195092           4.927895               B
  CTGF            connective tissue growth factor (Ctgf), mRNA.                                                 NM_010217.1                 2.193812           3.29075                E
  SCX             scleraxis (Scx), mRNA.                                                                        NM_198885.2                 2.185468           4.251521               B
  MUSTN1          musculoskeletal, embryonic nuclear protein 1 (Mustn1), mRNA.                                  NM_181390.1NM_181390.2      2.1853642.109783   3.9570883.099647       B
  HIST1H2BJ       histone cluster 1, H2bj (Hist1h2bj), mRNA.                                                    NM_178198.1                 2.173656           2.755197               H
  EEF1A2          eukaryotic translation elongation factor 1 alpha 2 (Eef1a2), mRNA.                            NM_007906.2                 2.153269           2.293173               A
  TNFRSF11B       tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) (Tnfrsf11b), mRNA.   NM_008764.3                 2.129809           9.058214               B
  HOXC6           homeo box C6 (Hoxc6), mRNA.                                                                   NM_010465.2                 2.107019           2.215212               
  2300002D11RIK   RIKEN cDNA 2300002D11 gene (2300002D11Rik), mRNA.                                             NM_001081156.1              2.097322           4.2774                 
  BDNF            brain derived neurotrophic factor (Bdnf), transcript variant 3, mRNA.                         NM_001048141.1              2.091327           7.461118               B
  HSPB8           heat shock protein 8 (Hspb8), mRNA.                                                           NM_030704.1                 2.090601           2.42948                H
  PDGFA           platelet-derived growth factor, alpha chain (Pdgfa) mRNA.                                                                 2.084386           2.631637               PD
  CCNG1           cyclin G1 (Ccng1), mRNA.                                                                      NM_009831.2                 2.083259           3.109058               CC
  HIST1H2BM       histone cluster 1, H2bm (Hist1h2bm), mRNA.                                                    NM_178200.1                 2.072647           2.824912               H
  HIST1H2BH       histone cluster 1, H2bh (Hist1h2bh), mRNA.                                                    NM_178197.1                 2.069317           2.693571               H
  HIST1H2BF       histone cluster 1, H2bf (Hist1h2bf), mRNA.                                                    NM_178195.1                 2.066524           2.55937                H
  COL7A1          collagen, type VII, alpha 1 (Col7a1), mRNA.                                                   NM_007738.3                 2.044317           3.129226               E
  A630005A06RIK   TBC1 domain family, member 2 (Tbc1d2), mRNA.                                                  NM_198664.3                 2.044002           3.518042               
  GSTP1           glutathione S-transferase, pi 1 (Gstp1), mRNA.                                                NM_013541.1                 2.039079           2.672256               
  TNFRSF12A       tumor necrosis factor receptor superfamily, member 12a (Tnfrsf12a), mRNA.                     NM_013749.1                 2.026671           3.449432               
  SNRPN           SNRPN upstream reading frame (Snurf), mRNA.                                                   NM_033174.2                 2.014161           3.736806               
  HIST1H2BK       histone cluster 1, H2bk (Hist1h2bk), mRNA.                                                    NM_175665.1                 2.012974           2.669902               H
  STMN2           stathmin-like 2 (Stmn2), mRNA.                                                                NM_025285.2                 2.007183           3.763786               B
  DOS             downstream of Stk11 (Dos), mRNA.                                                              NM_015761.2                 2.00261            3.474366               

Genes (52) upregulated by both microgravity and *Pthrp* ablation. All fold changes \> 2. All p values \< 0.05. Multiple entries for a gene indicate multiple probes. C: Clustering: A: apoptosis/survival, B: bone metabolism and bone morphogenic proteins, CC: cell cycle, E: extracellular matrix, H: histone, HS: heat shock, IC: ion channel, P: prolactins, PD: Platelet-derived growth factor, T: tumor growth factor, W: Wnt.

10.1371/journal.pone.0160034.t002

###### Genes (115) downregulated by both microgravity and *Pthrp* ablation.

![](pone.0160034.t002){#pone.0160034.t002g}

  Target ID       Definition (all probes: *Mus musculus*)                                                                              RefSeq ID                              Fold change 0g                Fold change ablation          C
  --------------- -------------------------------------------------------------------------------------------------------------------- -------------------------------------- ----------------------------- ----------------------------- ----
  SFRP2           secreted frizzled-related protein 2 (Sfrp2), mRNA.                                                                   NM_009144.1                            0.1316429                     0.096523                      W
  PTN             pleiotrophin (Ptn), mRNA.                                                                                            NM_008973.2                            0.1557338                     0.047141                      B
  IGFBP5          insulin-like growth factor binding protein 5 (Igfbp5), mRNA.                                                         NM_010518.2                            0.1603545                     0.2130594                     I
  1500015O10RIK   RIKEN cDNA 1500015O10 gene (1500015O10Rik), mRNA.                                                                    NM_024283.2                            0.1804316                     0.0975587                     
  IGF2            insulin-like growth factor 2 (Igf2), mRNA.                                                                           NM_010514.2                            0.2085582                     0.026108                      I
  CLU             PREDICTED: similar to clusterin (LOC100046120), mRNA.                                                                XM_001475611.1                         0.213665                      0.47421                       A
  CXCL12          chemokine (C-X-C motif) ligand 12 (Cxcl12), transcript variant 3, mRNA.                                              NM_013655.2NM_021704.2NM_001012477.1   0.21502010.22348560.236011    0.28323790.40775260.3778157   CH
  HP              haptoglobin (Hp), mRNA.                                                                                              NM_017370.1NM_017370.1                 0.22221020.4034571            0.18333460.4167181            B
  C3              complement 3 (C3) mRNA.                                                                                              NM_009778.1                            0.2325967                     0.1254136                     
  SCARA5          scavenger receptor class A, member 5 (putative) (Scara5), mRNA.                                                      NM_028903.1                            0.2351416                     0.1405516                     B
  LUM             lumican (Lum), mRNA.                                                                                                 NM_008524.1                            0.235224                      0.0573447                     E
  MRC1            mannose receptor, C type 1 (Mrc1), mRNA.                                                                             NM_008625.1                            0.253038                      0.0815048                     
  4930583H14RIK   RIKEN cDNA 4930583H14 gene (4930583H14Rik), mRNA.                                                                    NM_026358.2                            0.2575598                     0.1684547                     
  2310061N23RIK   interferon, alpha-inducible protein 27 (Ifi27), mRNA.                                                                NM_029803.1                            0.2600992                     0.0590283                     
  DCN             decorin (Dcn), mRNA.                                                                                                 NM_007833.4NM_007833.4                 0.28897940.3837174            0.06403410.0548521            E
  H19             H19 fetal liver mRNA (H19), non-coding RNA.                                                                          NR_001592.1                            0.2906019                     0.0360464                     E
  PPP1R3C         protein phosphatase 1, regulatory (inhibitor) subunit 3C (Ppp1r3c), mRNA.                                            NM_016854.2                            0.2954025                     0.1777717                     
  RBM3            PREDICTED: similar to RNA binding motif protein 3 (LOC100043257), mRNA.                                              XM_001480197.1                         0.2991486                     0.2378549                     A
  APOD            PREDICTED: similar to apolipoprotein D (LOC100047583), mRNA.                                                         XM_001479138.1                         0.2996465                     0.1742532                     A
  ITM2A           integral membrane protein 2A (Itm2a), mRNA.                                                                          NM_008409.2                            0.2997355                     0.138948                      B
  D930038M13RIK   ABI gene family, member 3 (NESH) binding protein (Abi3bp), transcript variant 1, mRNA.                               NM_178790.3                            0.3036303                     0.2955018                     B
  PFKL            phosphofructokinase, liver, B-type (Pfkl), mRNA.                                                                     NM_008826.3                            0.3054363                     0.2514627                     
  OLFML1          olfactomedin-like 1 (Olfml1), mRNA.                                                                                  NM_172907.2                            0.3123395                     0.3050197                     
  HIST1H2AD       histone cluster 1, H2ad (Hist1h2ad), mRNA.                                                                           NM_178188.3                            0.3149356                     0.0061305                     
  DLK1            delta-like 1 homolog (Drosophila) (Dlk1), mRNA.                                                                      NM_010052.4                            0.3273854                     0.1513731                     B
  HIST1H2AK       histone cluster 1, H2ak (Hist1h2ak), mRNA.                                                                           NM_178183.1                            0.3372404                     0.0596174                     H
  2310056P07RIK   family with sequence similarity 162, member A (Fam162a), mRNA.                                                       NM_027342.1                            0.3391683                     0.2567712                     
  HIST1H2AF       histone cluster 1, H2af (Hist1h2af), mRNA.                                                                           NM_175661.1                            0.3396376                     0.067387                      H
  SLC1A3          solute carrier family 1 (glial high affinity glutamate transporter), member 3 (Slc1a3), mRNA.                        NM_148938.2                            0.3399492                     0.1181837                     
  PSCDBP          cytohesin 1 interacting protein (Cytip), mRNA.                                                                       NM_139200.4                            0.3403133                     0.1328767                     
  NID2            nidogen 2 (Nid2), mRNA.                                                                                              NM_008695.2                            0.3477556                     0.3321977                     E
  TGFBI           transforming growth factor, beta induced (Tgfbi), mRNA.                                                              NM_009369.1                            0.3514812                     0.0792747                     T
  HIST1H2AH       histone cluster 1, H2ah (Hist1h2ah), mRNA.                                                                           NM_175659.1                            0.352093                      0.0777217                     
  FMO1            flavin containing monooxygenase 1 (Fmo1), mRNA.                                                                      NM_010231.2                            0.3568025                     0.3366457                     
  EGLN3           EGL nine homolog 3 (C. elegans) (Egln3), mRNA.                                                                       NM_028133.1                            0.3569504                     0.3106277                     
  DPEP2           dipeptidase 2 (Dpep2), mRNA.                                                                                         NM_176913.3                            0.35774720.3965119            0.14003250.18665              
  COL3A1          collagen, type III, alpha 1 (Col3a1), mRNA.                                                                          NM_009930.1                            0.3599768                     0.2207009                     E
  1200009O22RIK   RIKEN cDNA 1200009O22 gene (1200009O22Rik), mRNA.                                                                    NM_025817.3                            0.3616481                     0.3116025                     
  HIST1H2AO       histone cluster 1, H2ao (Hist1h2ao), mRNA.                                                                           NM_178185.1                            0.3618695                     0.057145                      H
  AGTR1A          angiotensin II receptor, type 1a (Agtr1a), mRNA.                                                                     NM_177322.2                            0.3640873                     0.3477361                     
  LDB2            LIM domain-binding protein 2 (Ldb2) mRNA.                                                                            NM_010698.2                            0.3694307                     0.2963222                     
  DPT             dermatopontin (Dpt), mRNA.                                                                                           NM_019759.2                            0.369822                      0.2973928                     E
  6330406I15RIK   RIKEN cDNA 6330406I15 gene (6330406I15Rik), mRNA.                                                                    NM_027519.1NM_027519.3                 0.37182430.3991528            0.19828060.2041744            
  RASSF4          Ras association (RalGDS/AF-6) domain family member 4 (Rassf4), mRNA.                                                 NM_178045.3NM_178045.3                 0.3723380.3845508             0.36712360.1214973            
  PDGFRA          platelet derived growth factor receptor, alpha polypeptide (Pdgfra), transcript variant 1, mRNA.                     NM_011058.2                            0.3755132                     0.394926                      PD
  HIST1H2AN       histone cluster 1, H2an (Hist1h2an), mRNA.                                                                           NM_178184.1                            0.3776532                     0.0945669                     H
  ZCCH5           Zinc finger, CCHC domain-containing 5 (Zcchc5), mRNA                                                                 NM_199468.2                            0.3839341                     0.4813192                     
  IGFBP3          insulin-like growth factor binding protein 3 (Igfbp3), mRNA.                                                         NM_008343.2                            0.3878084                     0.3767934                     I
  AOC3            amine oxidase, copper containing 3 (Aoc3), mRNA.                                                                     NM_009675.1                            0.390921                      0.102008                      
  KNG1            kininogen 1 (Kng1), mRNA.                                                                                            NM_023125.2                            0.3914529                     0.2682237                     
  SERPING1        serine (or cysteine) peptidase inhibitor, clade G, member 1 (Serping1), mRNA.                                        NM_009776.1                            0.3939361                     0.2493484                     
  SFRP1           secreted frizzled-related protein 1 (Sfrp1), mRNA.                                                                   NM_013834.1                            0.3966504                     0.1332278                     W
  EMR1            EGF-like module containing, mucin-like, hormone receptor-like sequence 1 (Emr1), mRNA.                               NM_010130.3                            0.4002873                     0.0452258                     
  SIRPB1          signal-regulatory protein beta 1 (Sirpb1), transcript variant 3, mRNA.                                               NM_001002898.1                         0.4006563                     0.250706                      
  CAR9            carbonic anhydrase 9 (Car9), mRNA.                                                                                   NM_139305.1                            0.401926                      0.3807879                     
  SRPX            sushi-repeat-containing protein (Srpx), mRNA.                                                                        NM_016911.4NM_016911.4                 0.40437110.4169736            0.12827860.1438187            
  LBP             lipopolysaccharide binding protein (Lbp), mRNA.                                                                      NM_008489.2                            0.4046987                     0.3596355                     
  2310006J04RIK   Ankyrin repeat domain 37 (Ankrd 37), mRNA                                                                            NM_001039562.1                         0.4075139                     0.4461992                     
  CCR5            chemokine (C-C motif) receptor 5 (Ccr5), mRNA.                                                                       NM_009917.2NM_009917.2NM_009917.4      0.40916990.44612370.4461237   0.31747080.32485210.3880605   CH
  RAMP2           receptor (calcitonin) activity modifying protein 2 (Ramp2), mRNA.                                                    NM_019444.2                            0.4105468                     0.2878545                     B
  LSP1            PREDICTED: predicted gene, ENSMUSG00000043795 (ENSMUSG00000043795), mRNA.                                            XM_001480835.1                         0.4114556                     0.1243922                     
  CDKN1C          cyclin-dependent kinase inhibitor 1C (P57) (Cdkn1c), mRNA.                                                           NM_009876.3                            0.4116614                     0.347614                      CC
  CORO1A          coronin, actin binding protein 1A (Coro1a), mRNA.                                                                    NM_009898.2NM_009898.2NM_009898.2      0.41277540.44359450.4970813   0.08707340.05964910.1696803   
  C1QA            complement component 1, q subcomponent, alpha polypeptide (C1qa), mRNA.                                              NM_007572.2                            0.4128893                     0.1927809                     
  SLC2A1          solute carrier family 2 (facilitated glucose transporter), member 1 (Slc2a1), mRNA.                                  NM_011400.2                            0.4167042                     0.2991707                     
  GPR23           G protein-coupled receptor 23 (Gpr23), mRNA.                                                                         NM_175271.2                            0.4254305                     0.4447173                     
  PDK1            pyruvate dehydrogenase kinase, isoenzyme 1 (Pdk1), nuclear gene encoding mitochondrial protein, mRNA.                NM_172665.3                            0.4255101                     0.3667602                     
  CTSC            cathepsin C (Ctsc), mRNA.                                                                                            NM_009982.2                            0.4265272                     0.0758005                     E
  OASL2           2\'-5\' oligoadenylate synthetase-like 2 (Oasl2), mRNA.                                                              NM_011854.1                            0.4272569                     0.1159377                     
  C1QB            complement component 1, q subcomponent, beta polypeptide (C1qb), mRNA.                                               NM_009777.2                            0.4278048                     0.0245339                     
  DAB2            disabled homolog 2 (Drosophila) (Dab2), transcript variant 2, mRNA.                                                  NM_023118.1NM_001008702.1              0.42782040.4450885            0.17925610.1341114            B
  RSPO3           R-spondin 3 homolog (Xenopus laevis) (Rspo3), mRNA.                                                                  NM_028351.2                            0.4293909                     0.2896171                     W
  MFAP2           microfibrillar-associated protein 2 (Mfap2), mRNA.                                                                   NM_008546.2NM_008546.2NM_008546.2      0.42967080.47591550.4945922   0.18086140.25899670.2757687   B
  GMFG            glia maturation factor, gamma (Gmfg), transcript variant 1, mRNA.                                                    NM_022024.2NM_022024.2                 0.43023620.4870403            0.203090.2355645              
  SELENBP1        PREDICTED: hypothetical protein LOC100044204 (LOC100044204), mRNA.                                                   XM_001471696.1                         0.433163                      0.2613255                     
  MEST            mesoderm specific transcript (Mest), mRNA.                                                                           NM_008590.1NM_008590.1                 0.43492520.4556044            0.31959320.3918639            
  NDRG1           N-myc downstream regulated gene 1 (Ndrg1), mRNA.                                                                     NM_008681.2                            0.4352534                     0.3870171                     
  MS4A6D          membrane-spanning 4-domains, subfamily A, member 6D (Ms4a6d), mRNA.                                                  NM_026835.2                            0.4373044                     0.0358791                     
  ALOX5AP         arachidonate 5-lipoxygenase activating protein (Alox5ap), mRNA.                                                      NM_009663.1                            0.4387523                     0.0317102                     
  HIST1H2AG       histone cluster 1, H2ag (Hist1h2ag), mRNA.                                                                           NM_178186.2                            0.4395184                     0.2645484                     H
  1300002F13RIK   ERBB receptor feedback inhibitor 1 (Errfi1), mRNA.                                                                   NM_133753.1                            0.4395548                     0.2132049                     
  EVI2A           ecotropic viral integration site 2a (Evi2a), transcript variant 2, mRNA.                                             NM_010161.3                            0.4402088                     0.1280774                     
  CXCL4           chemokine (C-X-C motif) ligand 4 (Cxcl4), mRNA.                                                                      NM_019932.2                            0.4419611                     0.180652                      CH
  1190002H23RIK   RIKEN cDNA 1190002H23 gene (1190002H23Rik), mRNA.                                                                    NM_025427.2                            0.4430251                     0.3481645                     
  ENO1            enolase 1, alpha non-neuron (Eno1), mRNA.                                                                            NM_023119.1                            0.4461543                     0.4872021                     B
  LYZ             lysozyme 1 (Lyz1), mRNA.                                                                                             NM_013590.3                            0.4473266                     0.3851333                     
  CD52            CD52 antigen (Cd52), mRNA.                                                                                           NM_013706.1                            0.44963                       0.0749331                     
  NDRL            N-myc downstream gene 1 (Ndrl), mRNA.                                                                                                                       0.4504366                     0.4056498                     
  CYP7B1          cytochrome P450, family 7, subfamily b, polypeptide 1 (Cyp7b1), mRNA.                                                NM_007825.3                            0.450876                      0.1997939                     
  PIRA4           paired-Ig-like receptor A4 (Pira4), mRNA.                                                                            NM_011091.1                            0.4527747                     0.0263051                     
  RARRES2         retinoic acid receptor responder (tazarotene induced) 2 (Rarres2), mRNA.                                             NM_027852.1                            0.4537163                     0.3671236                     
  CD14            CD14 antigen (Cd14), mRNA.                                                                                           NM_009841.3                            0.4582975                     0.1117494                     B
  ALDH3B1         aldehyde dehydrogenase 3 family, member B1 (Aldh3b1), mRNA.                                                          NM_026316.2                            0.4627661                     0.3188771                     
  KCNAB2          potassium voltage-gated channel, shaker-related subfamily, beta member 2 (Kcnab2), mRNA.                             NM_010598.2                            0.4659567                     0.1179869                     
  C1QG            complement component 1, q subcomponent, C chain (C1qc), mRNA.                                                        NM_007574.2                            0.468035                      0.3163972                     
  GALNT9          UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 9 (Galnt9), mRNA.                   NM_198306.1                            0.4683551                     0.3906375                     
  ADD3            adducin 3 (gamma) (Add3), mRNA.                                                                                      NM_013758.2                            0.4687887                     0.306828                      
  ZFP36L1         zinc finger protein 36, C3H type-like 1 (Zfp36l1), mRNA.                                                             NM_007564.4                            0.4703194                     0.2280471                     
  HEMP1           NCK associated protein 1 like (Nckap1l), mRNA.                                                                       NM_153505.4                            0.4709411                     0.0826084                     B
  2810046M22RIK                                                                                                                        NM_026621.1                            0.4778584                     0.4976117                     
  LGMN            legumain (Lgmn), mRNA.                                                                                               NM_011175.2                            0.4770529                     0.2286424                     B
  TXNIP           thioredoxin interacting protein (Txnip), transcript variant 1, mRNA.                                                 NM_001009935.2                         0.4827267                     0.3327381                     B
  EHD4            EH-domain containing 4 (Ehd4), mRNA.                                                                                 NM_133838.4                            0.483588                      0.3327381                     E
  EMR1            EGF-like module containing, mucin-like, hormone receptor-like sequence 1 (Emr1), mRNA.                               NM_010130.1                            0.4839607                     0.1299728                     
  ARHGAP20        Rho GTPase activating protein 20 (Arhgap20), mRNA.                                                                   NM_175535.3                            0.4859805                     0.4102931                     
  PTX3            pentaxin related gene (Ptx3) mRNA                                                                                    NM_008987.2                            0.4867727                     0.1136763                     B
  NCF4            neutrophil cytosolic factor 4 (Ncf4), mRNA.                                                                          NM_008677.1                            0.4881307                     0.1080301                     
  PFC             complement factor properdin (Cfp), mRNA.                                                                             NM_008823.3                            0.488737                      0.0720321                     
  SMARCA1         SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 1 (Smarca1), mRNA.   NM_053123.3                            0.4911543                     0.3176144                     
  FCER1G          Fc receptor IgE high affinity 1 gamma polypeptide (Fcerg) mRNA.                                                      NM_010185.2                            0.4915371                     0.0163625                     
  CENPA           centromere protein A (Cenpa), mRNA.                                                                                  NM_007681.2                            0.4943203                     0.0808812                     
  1200002N14RIK   RIKEN cDNA 1200002N14 gene (1200002N14Rik), mRNA.                                                                    NM_027878.2                            0.4949315                     0.207954                      
  TK1             thymidine kinase 1 (Tk1), mRNA.                                                                                      NM_009387.1                            0.4950169                     0.1742371                     
  ALDOA           aldolase A, fructose-bisphosphate (Aldoa), mRNA.                                                                     NM_007438.3                            0.4959253                     0.4941576                     
  SLPI            secretory leukocyte peptidase inhibitor (Slpi), mRNA.                                                                NM_011414.2                            0.4988716                     0.2429238                     

Genes (115) downregulated by both microgravity and *Pthrp* ablation. All fold changes \< 0.5. All p values \< 0.05. Multiple entries for a gene indicate multiple probes. C: Clustering: A: apoptosis/survival, B: bone metabolism and bone morphogenic proteins, CC: cell cycle, CH: chemokines, E: extracellular matrix, H: histone, I: Insulin-like growth factor, PD: Platelet-derived growth factor, T: tumor growth factor, W: Wnt.

Because the PTHrP~1-36~ anabolic agent was observed to compensate for weightlessness and reverse the effects of microgravity exposure in TOs (Figs [1](#pone.0160034.g001){ref-type="fig"}, [2](#pone.0160034.g002){ref-type="fig"} and [3](#pone.0160034.g003){ref-type="fig"}), microarray analysis was conducted on *Pthrp*^*+/+*^ TOs at 0*g* treated intermittently with 10^-8^M PTHrP~1-36~ for 6 days. The expression levels of 102 genes were upregulated and 61 downregulated (total 163, fold change \>1.5 or \<0.65, *p* value\< 0.05, complete list in [S4A and S4B Table](#pone.0160034.s005){ref-type="supplementary-material"}). Although the treatment peptide corresponds to only 36 amino acids from the N-terminus of PTHrP and not the whole sequence, we expect reversal of some effects induced by microgravity and/or *Pthrp* ablation. Accordingly, 27 of the 0*g*-upregulated genes (45.7%), and 34 of the ablation-upregulated genes (12.5%) were downregulated by PTHrP~1-36~ treatment. Of those, 24 genes were common to all three conditions ([Fig 5C](#pone.0160034.g005){ref-type="fig"}, listed in [Table 3](#pone.0160034.t003){ref-type="table"}). 53 of the 0*g*-downregulated (41%) and 95 of the ablation-downregulated genes (19.2%) were upregulated by PTHrP~1-36~ treatment. Of those, 50 genes were common to all three conditions ([Fig 5D](#pone.0160034.g005){ref-type="fig"}, listed in [Table 4](#pone.0160034.t004){ref-type="table"}). Clustering analysis revealed the same functional gene categories as above. None of the significantly-affected genes presented a contradictory direction change in expression level between PTHrP~1-36~ treatment and *Pthrp* ablation or microgravity treatment ([S1 Fig](#pone.0160034.s001){ref-type="supplementary-material"}).

10.1371/journal.pone.0160034.t003

###### Genes (24) upregulated by both *Pthrp* ablation and microgravity and downregulated by PTHrP~1-36~ treatment.

![](pone.0160034.t003){#pone.0160034.t003g}

  Target ID   Definition (all probes: *Mus musculus*)                                                       RefSeqID                    Fold change PTHrP 1--36 treatment   C
  ----------- --------------------------------------------------------------------------------------------- --------------------------- ----------------------------------- ----
  AQP5        aquaporin 5 (Aqp5), mRNA.PREDICTED: similar to aquaporin 5 (LOC100046616), mRNA.              NM_009701.4XM_001476512.1   0.37050890.4987479                  A
  TNFRSF11B   tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) (Tnfrsf11b), mRNA.   NM_008764.3                 0.4687011                           B
  HSPB1       heat shock protein 1 (Hspb1), mRNA.                                                           NM_013560.1                 0.4871401                           HS
  MRPPLF3     prolactin family 2, subfamily c, member 4 (Prl2c4), mRNA.                                     NM_011954.2                 0.5052176                           P
  NKD2        naked cuticle 2 homolog (Drosophila) (Nkd2), mRNA.                                            NM_028186.3                 0.5150308                           W
  PLF2        prolactin family 2, subfamily c, member 3 (Prl2c3), mRNA.                                     NM_011118.1                 0.5191368                           P
  BDNF        brain derived neurotrophic factor (Bdnf), transcript variant 3, mRNA.                         NM_001048141.1              0.5334656                           B
  TIMP3       tissue inhibitor of metalloproteinase 3 (Timp3), mRNA.                                        NM_011595.2NM_011595.2      0.53376130.6267908                  E
  CRYAB       crystallin, alpha B (Cryab), mRNA.                                                            NM_009964.1                 0.5387105                           B
  ASS1        argininosuccinate synthetase 1 (Ass1), mRNA.                                                  NM_007494.3                 0.5595178                           
  ESD         esterase D/formylglutathione hydrolase (Esd), mRNA.                                           NM_016903.2                 0.5693265                           
  INHBA       inhibin beta-A (Inhba), mRNA.                                                                 NM_008380.1                 0.5792015                           B
  CD44        CD44 antigen (Cd44), transcript variant 2, mRNA                                               NM_001039150.1              0.5834                              B
  GREM1       gremlin1 (Grem1) mRNA.                                                                        NM_011824.1                 0.5978743                           B
  GDF15       growth differentiation factor 15 (Gdf15), mRNA.                                               NM_011819.1                 0.5985932                           T
  MUSTN1      musculoskeletal, embryonic nuclear protein 1 (Mustn1), mRNA.                                  NM_181390.1                 0.6015734                           B
  MDM2        transformed mouse 3T3 cell double minute 2 (Mdm2), mRNA.                                      NM_010786.2                 0.6034403                           
  KCTD10      potassium channel tetramerisation domain containing 10 (Kctd10), mRNA.                        NM_026145.3                 0.61132                             IC
  EEF1A2      eukaryotic translation elongation factor 1 alpha 2 (Eef1a2), mRNA.                            NM_007906.2                 0.6231256                           A
  WHRN        whirlin (Whrn), transcript variant 3, mRNA                                                    NM_001008792.1              0.6237                              
  EPHX1       epoxide hydrolase 1, microsomal (Ephx1), mRNA                                                 NM_010145.2                 0.6255                              
  HIST1H4H    histone cluster 1, H4h (Hist1h4h), mRNA                                                       NM_153173.2                 0.635                               H
  STMN2       stathmin-like 2 (Stmn2), mRNA                                                                 NM_025285.2                 0.645                               B
  SCX         scleraxis (Scx), mRNA.                                                                        NM_198885.2                 0.6553575                           B

All -fold changes \< 0.66, all p values \< 0.05. Multiple entries for a gene indicate multiple probes. C: Clustering: A: apoptosis/survival, B: bone metabolism and bone morphogenic proteins, E: extracellular matrix, H: histone, HS: heat shock, IC: ion channel, P: prolactin, T: tumor growth factor, W: Wnt.

10.1371/journal.pone.0160034.t004

###### Genes (50) downregulated by both *Pthrp* ablation and microgravity and upregulated by PTHrP~1-36~ treatment.

![](pone.0160034.t004){#pone.0160034.t004g}

  Target ID       Definition (all probes: *Mus musculus*)                                                                              RefSeqID         Fold change PTHrP 1--36 treatment   C
  --------------- -------------------------------------------------------------------------------------------------------------------- ---------------- ----------------------------------- ----
  RBM3            PREDICTED: similar to RNA binding motif protein 3 (LOC100043257), mRNA.                                              XM_001480197.1   3.316729                            A
  HIST1H2AD       histone cluster 1, H2ad (Hist1h2ad), mRNA.                                                                           NM_178188.3      3.070246                            H
  HIST1H2AH       histone cluster 1, H2ah (Hist1h2ah), mRNA.                                                                           NM_175659.1      2.644405                            H
  HIST1H2AN       histone cluster 1, H2an (Hist1h2an), mRNA.                                                                           NM_178184.1      2.629741                            H
  HIST1H2AK       histone cluster 1, H2ak (Hist1h2ak), mRNA.                                                                           NM_178183.1      2.619065                            H
  PTN             pleiotrophin (Ptn), mRNA.                                                                                            NM_008973.2      2.610166                            B
  HIST1H2AF       histone cluster 1, H2af (Hist1h2af), mRNA.                                                                           NM_175661.1      2.590586                            H
  HIST1H2AO       histone cluster 1, H2ao (Hist1h2ao), mRNA.                                                                           NM_178185.1      2.363633                            H
  2310061N23RIK   interferon, alpha-inducible protein 27 (Ifi27), mRNA.                                                                NM_029803.1      2.240007                            A
  CENPA           centromere protein A (Cenpa), mRNA.                                                                                  NM_007681.2      2.217246                            
  HIST1H2AG       histone cluster 1, H2ag (Hist1h2ag), mRNA.                                                                           NM_178186.2      2.186001                            H
  LUM             lumican (Lum), mRNA.                                                                                                 NM_008524.1      2.127828                            E
  ITM2A           integral membrane protein 2A (Itm2a), mRNA.                                                                          NM_008409.2      2.072151                            B
  IGFBP5          insulin-like growth factor binding protein 5 (Igfbp5), mRNA.                                                         NM_010518.2      2.068563                            I
  DCN             decorin (Dcn), mRNA.                                                                                                 NM_007833.4      2.0663121.731693                    E
  1500015O10RIK   RIKEN cDNA 1500015O10 gene (1500015O10Rik), mRNA.                                                                    NM_024283.2      1.860714                            
  MFAP2           microfibrillar-associated protein 2 (Mfap2), mRNA.                                                                   NM_008546.2      1.8432941.5754411.501827            B
  TK1             thymidine kinase 1 (Tk1), mRNA                                                                                       NM_009387.1      1.8403                              
  ALOX5AP         arachidonate 5-lipoxygenase activating protein (Alox5ap), mRNA                                                       NM_009663.1      1.8329                              
  CDKN1C          cyclin-dependent kinase inhibitor 1C (P57) (Cdkn1c), mRNA.                                                           NM_009876.3      1.797543                            CC
  GPR23           G protein-coupled receptor 23 (Gpr23), mRNA                                                                          NM_175271.2      1.7145                              
  CD52            CD52 antigen (Cd52), mRNA.                                                                                           NM_013706.1      1.688404                            
  C1QA            complement component 1, q subcomponent, alpha polypeptide (C1qa), mRNA.                                              NM_007572.2      1.685787                            
  CTSC            cathepsin C (Ctsc), mRNA.                                                                                            NM_009982.2      1.68393                             E
  ALDH3B1         aldehyde dehydrogenase 3 family, member B1 (Aldh3b1), mRNA.                                                          NM_026316.2      1.678022                            
  TGFBI           transforming growth factor, beta induced (Tgfbi), mRNA.                                                              NM_009369.1      1.664148                            T
  FMO1            flavin containing monooxygenase 1 (Fmo1), mRNA.                                                                      NM_010231.2      1.657767                            
  IGF2            insulin-like growth factor 2 (Igf2), mRNA.                                                                           NM_010514.2      1.656335                            I
  CYP7B1          cytochrome P450, family 7, subfamily b, polypeptide 1 (Cyp7b1), mRNA.                                                NM_007825.3      1.652679                            
  CXCL12          chemokine (C-X-C motif) ligand 12 (Cxcl12) mRNA.                                                                     NM_013655.2      1.637518                            CH
  LDB2            LIM domain-binding 2 (Ldb2) mRNA.                                                                                    NM_010698.2      1.634978                            
  CORO1A          coronin, actin binding protein 1A (Coro1a), mRNA.                                                                    NM_009898.2      1.6294451.620518                    
  EMR1            EGF-like module containing, mucin-like, hormone receptor-like sequence 1 (Emr1), mRNA.                               NM_010130.3      1.626247                            
  KNG1            kininogen 1 (Kng1), mRNA.                                                                                            NM_023125.2      1.5999                              
  OLFML1          olfactomedin-like 1 (Olfml1), mRNA.                                                                                  NM_172907.2      1.599738                            
  AOC3            amine oxidase, copper containing 3 (Aoc3), mRNA.                                                                     NM_009675.1      1.598282                            
  GMFG            glia maturation factor, gamma (Gmfg), transcript variant 1, mRNA.                                                    NM_022024.2      1.5965611.532455                    
  NCF4            neutrophil cytosolic factor 4 (Ncf4), mRNA.                                                                          NM_008677.1      1.593552                            
  SFRP2           secreted frizzled-related protein 2 (Sfrp2), mRNA.                                                                   NM_009144.1      1.589225                            W
  SMARCA1         SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 1 (Smarca1), mRNA.   NM_053123.3      1.5706                              
  SIRPB1          signal-regulatory protein beta 1 (Sirpb1), transcript variant 3, mRNA.                                               NM_001002898.1   1.559451                            
  RASSF4          Ras association (RalGDS/AF-6) domain family member 4 (Rassf4), mRNA.                                                 NM_178045.3      1.558789                            
  KCNAB2          potassium voltage-gated channel, shaker-related subfamily, beta member 2 (Kcnab2), mRNA.                             NM_010598.2      1.556591                            IC
  LSP1            PREDICTED: predicted gene, ENSMUSG00000043795 (ENSMUG00000043795), mRNA                                              XM_001480835.1   1.5468                              
  COL3A1          collagen, type III, alpha 1 (Col3a1), mRNA.                                                                          NM_009930.1      1.531741                            E
  SRPX            sushi-repeat-containing protein (Srpx), mRNA.                                                                        NM_016911.4      1.522525                            
  DAB2            disabled 2 mitogen-responsive phosphoprotein (Dab2) mRNA                                                             NM_023118.1      1.519832                            
  EVI2A           ecotropic viral integration site 2a (Evi2a), transcript variant 2, mRNA.                                             NM_010161.3      1.517936                            
  NID2            nidogen 2 (Nid2), mRNA.                                                                                              NM_008695.2      1.506611                            E
  C1QB            complement component 1, q subcomponent, beta polypeptide (C1qb), mRNA.                                               NM_009777.2      1.503228                            

All -fold changes \> 1.5, all p values \< 0.05. C: Clustering: A: apoptosis/survival, B: bone metabolism and bone morphogenic proteins, CC: cell cycle, CH: chemokines, E: extracellular matrix, H: histone, I: Insulin-like growth factor, IC: ion channel, T: tumor growth factor, W: Wnt.

Discussion {#sec020}
==========

Exposure to Space microgravity causes an important and rapid decrease in the BMD of astronauts' weight-bearing bones similar to that observed in disuse osteoporosis on Earth \[[@pone.0160034.ref045]\]. Exercise in weightless conditions does not effectively counter spine and hip bone loss, and a better understanding of bone formation/resorption uncoupling mechanisms under these conditions is needed in order to provide effective countermeasures useful to flight personnel as well as to patients suffering from disuse-induced osteoporosis on Earth. Microgravity has been reported to reduce the expression of PTHrP in lung and bone cells, leading to speculation that this molecule can act as a gravisensor \[[@pone.0160034.ref033]\]. In view of the fact that bone loss appears to result in significant part from osteoblast dysfunction, we investigated the mechanistic implications of PTHrP metabolism in 0*g*-induced skeletal disorders using mouse wild-type trabecular osteoblasts (*Pthrp*^*+/+*^) which mimic astronauts' TOs at the start of their mission. Comparison of viability of the wild-type cells with *Pthrp*^*+/-*^ and ^-/-^ TOs confirmed the involvement of PTHrP in resistance to microgravity: a 6-day exposure to microgravity (actual and simulated) significantly decreased viability of *Pthrp*^*-/-*^ trabecular osteoblasts while *Pthrp*^*+/+*^ cells appeared unaffected. An allelic dose-effect for PTHrP expression was even observed using heterozygous *Pthrp*^*+/-*^ TOs in simulated 0*g*. Although *Pthrp*^*+/+*^ cells maintained viability after 6 days at 0*g*, a crucial observation made during exposure of TOs to longer periods of simulated microgravity revealed that the astronaut-mimicking *Pthrp*^*+/+*^ TOs start to lose viability at 2 weeks, suggesting early metabolic changes in the wild-type cells at 0*g*. Importantly, this sharp decline in viability could be countered by treatment with 10^-8^M PTHrP~1-36~ peptide which, when administered intermittently (in a pulsatile manner), has anabolic properties, in contrast with a continuous treatment which causes downregulation of osteogenic genes \[[@pone.0160034.ref036]\]. These observations confirmed the role of PTHrP in cell survival in microgravity in trabecular osteoblasts. In the present study, calvarial osteoblasts appeared much less sensitive to 0*g* conditions than trabecular osteoblasts, an observation which agrees with those made in human 6° head-down bedrest prolonged tests (which effectively mimic weightlessness) where weight-bearing bones incur substantial skeletal loss but cranium bones in fact appear to gain bone mass \[[@pone.0160034.ref046]\].

The mechanisms by which PTHrP counters the signal of absent gravity were investigated through expression array analyses revealing that radical changes were already occurring in *Pthrp*^*+/+*^ TOs after 6 days in microgravity. Strikingly, the genes affected by 0*g* present an 87% overlap with genes affected by *Pthrp* ablation (comparison of *Pthrp*^*+/+*^ and *Pthrp*^*-/-*^ TOs at 1*g*), and all changes proceed in the same direction for ablation and 0*g* exposure. This observation indicates that microgravity-induced metabolic changes in wild-type trabecular osteoblasts proceed mostly through PTHrP-controlled genes, affirming a prominent role of PTHrP in cell survival under microgravity. Among the most up- or downregulated genes common to 0*g* and *Pthrp* ablation are genes encoding members of the prolactin family, several genes involved in bone growth including Wnt signaling and insulin-like growth factor (IGF) signaling, genes encoding extracellular matrix (ECM)-related proteins and involved in BMP metabolism and, in mineralization, heat-shock proteins, chemokines, and genes encoding apoptosis/survival, cell cycle control as well as histones. A comparison of our microarray results with expression changes in wild-type mouse 2T3 pre-osteoblasts attached to growth container surface and exposed to simulated 0g for 3 days \[[@pone.0160034.ref047]\] confirms the loss of bone growth, mineralization, bone morphogenic and extra-cellular matrix proteins upon exposure to simulated microgravity by similar changes in expression of numerous common genes at 0g: osteoprotegerin, RAMP 2, lumican, decorin and various collagen proteins. Several cell signaling molecules are also similarly affected by microgravity in both studies: PDGFRα, IGF2, SFRP2, and members of the TNF and Fos family. The Wnt/βcatenin pathway is essential for bone formation in response to mechanical loading \[[@pone.0160034.ref048]\], and in our study, expression of mechanosensitive genes such as SFRP1 and 2 which regulate the Wnt pathway \[[@pone.0160034.ref049]\] was very strongly inhibited by exposure to 0g. This implicates the PTHrP pathway in this mechansensitive pathway in microgravity conditions, and agrees with results of Maycas *et al* \[[@pone.0160034.ref050]\] who report the involvement of PTH1R as a mechanosensor in osteocyte survival and Chen et al \[[@pone.0160034.ref051]\] who suggest PTHrP as a candidate mediator of the anabolic effects of mechanical force on bone.

Intermittent treatment with PTHrP~1-36~ of TOs not only reversed loss of viability (in short and long 0*g* exposures) but reversed expression changes in a significant proportion of the genes affected by microgravity. PTHrP~1-36~ also reversed many, but a lesser number, of the changes in gene expression modified by *Pthrp* ablation. In that respect, it must be noted that PTHrP~1-36~ will impact genes controlled by the N-terminus of PTHrP, and likely not genes controlled by the protein's mid-region and C-terminus. Furthermore, reversal responses are likely to be dependent on PTHrP~1-36~ concentration, and a dose-response curve would need to be examined for its influence on genes not affected here which might be modified by higher concentrations of PTHrP~1-36~.

Of particular interest are the genes whose expression change in 0*g* was reversed by intermittent PTHrP~1-36~ treatment as their activity is clearly linked to the maintenance of viability obtained in wild-type TOs treated during long periods at 0*g*. The 74 genes (24 + 50 from central intersects in [Fig 5C and 5D](#pone.0160034.g005){ref-type="fig"}, common to ablation and 0*g* and reversed by PTHrP~1-36~) belong to similar clustering categories as above. Among the reversals caused by treatment, some strong candidates for microgravity-induced osteoporotic involvement appear. Two genes (*Mrpplf3* and *Plf2*) that belong to the prolactin family were among the most highly-upregulated. Prolactins are hormones secreted by the pituitary gland and some extra-pituitary tissues. Mitogen-regulated protein/proliferin (MRP/PLF) proteins are members of the prolactin gene family involved in developmental processes. Prolactins have pleiotrophic actions in lactation and many other biological functions, and their expression is regulated by PTHrP \[[@pone.0160034.ref052], [@pone.0160034.ref053]\]. Exposure of pregnant rats to prolactins causes reduced ossification in pups \[[@pone.0160034.ref054]\], and abnormally high prolactin expression encountered in human conditions such as hyperprolactinemic hypogonadism, extended lactation, or as a consequence of the use of some anti-psychotic drugs, is associated with acute skeletal loss \[[@pone.0160034.ref055]--[@pone.0160034.ref057]\]. Our results indicate that exposure to 0*g* strikingly (by 12-fold) upregulates expression of prolactin genes *Mrpplf3* and *Plf2*, with highly-efficient reversal by PTHrP~1-36~. Our observations agree with reports that Spaceflight increases prolactin levels in rats \[[@pone.0160034.ref058]\], and that exposure of healthy male volunteers to head-down bed rest causes significant elevation of prolactin levels \[[@pone.0160034.ref059]\]. Our results demonstrate expression of prolactin genes in osteoblastic cells and implicate their products in a major bone loss event that is PTHrP-controlled and unrelated to lactation.

The most highly-downregulated gene by both 0*g* and *Pthrp* ablation with reversal by PTHrP~1-36~ is *Rbm3* which encodes RNA-binding motif protein 3, an inhibitor of apoptosis \[[@pone.0160034.ref060], [@pone.0160034.ref061]\]. Its expression is upregulated by PTHrP~1-36~ which prevents TO death, suggesting *Rbm3* involvement in loss of viability and cell death observed at 0g and after ablation. Several genes encoding proteins involved in bone growth, mineralization, BMP and extracellular matrix metabolism are significantly upregulated (*Tnfrsf11b*, *Bdnf*, *Timp3*, *Cryab*, *Grem1*, *Inhba*, *Mustn1*, *Scx*) or downregulated (*Ptn*, *Itm2a*, *Lum*, *Dcn*, *Mfap2*, *Ctsc*, *Col3a1*, *Nid2*) by both 0*g* and *Pthrp* ablation. Of interest among others, the highly-downregulated *Ptn* gene encodes pleitrophin, an osteoblast-secreted matrix-associated heparin-binding protein which enhances osteogenic differentiation of bone marrow cells \[[@pone.0160034.ref062]\]. *Tnfrsf11b* which encodes osteoprotegerin, the decoy to the receptor activator of nuclear factor kappa-B ligand (RANKL), regulates bone mass by inhibiting osteoclast differentiation and activation. It was found in our study to be strongly upregulated by both microgravity and *Pthrp* ablation in trabecular osteoblasts but downregulated by 0*g* in calvarial osteoblasts \[[@pone.0160034.ref063]\], suggesting a role in TO and CO different behaviors in microgravity. Also strongly upregulated is *Timp3* (encoding tissue inhibitor of metalloprotease 3) which regulates ECM calcium deposition, and whose overexpression prevents osteoblast differentiation \[[@pone.0160034.ref064]\]. Gremlin overexpression is known to cause osteopenia and conditional deletion increases bone mass \[[@pone.0160034.ref065], [@pone.0160034.ref066]\], in agreement with our observation that 0g and ablation upregulate *Grem1*. Members of the IGF and chemokine families are downregulated by 0*g* and *Pthrp* ablation with reversal by PTHrP~1-36~. *Igf2* increases bone formation and bone apposition rates \[[@pone.0160034.ref067], [@pone.0160034.ref068]\], and *Igfbp5* stimulates osteoblast proliferation \[[@pone.0160034.ref069]\]. Chemokine ligand Cxcl12 expression accompanies osteoblast differentiation \[[@pone.0160034.ref070]\] and its downregulation suggests loss of osteoblast characteristics. All of the above changes point to rapid and profound modifications in trabecular osteoblast metabolism in 0*g* conditions.

The fact that bone loss in flight personnel is reversible to a certain extent upon return to Earth \[[@pone.0160034.ref005], [@pone.0160034.ref071], [@pone.0160034.ref072]\] indicates a major difference between Space-induced secondary osteoporosis and the primary aging-associated osteoporosis which is largely irreversible in absence of pharmacologic intervention. It is also interesting to note that in genome-wide association studies, genes associated with aging-related BMD loss do not overlap with those highlighted in our study except for PTHrP \[[@pone.0160034.ref073]\], osteoprotegerin \[[@pone.0160034.ref074]\], and *Ptn* \[[@pone.0160034.ref075], [@pone.0160034.ref076]\] suggesting mechanistic differences in bone loss control between these two types of osteoporosis.

Conclusions {#sec021}
===========

In this study, we present *in vitro* evidence that naturally-expressed PTHrP in TOs has an important anti-apoptotic function in weightless conditions. Our results confirm a survival role for PTHrP in microgravity-exposed osteoblasts, and identify molecules of interest for further investigation in order to find efficient targets for prevention of bone loss due to skeletal unloading. In particular, the involvement of members of the prolactin family suggests a novel mechanistic hypothesis for transmission of the weightlessness stimulus. The role of PTHrP in maintaining low levels of prolactins may be crucial to prevent microgravity-induced osteoporosis and, by extension, disuse osteoporosis.

Supporting Information {#sec022}
======================

###### Matrix table (pair-wise combination) of common genes.

The 4 genes downregulated by both 0*g* and PTHrP~1-36~ treatment are *Fos*, *Zfp36*, *Pvrlz* and *JunB*.

(TIF)

###### 

Click here for additional data file.

###### Summary of experimental conditions aboard satellite Foton M3.

Pre-programmed valves allowed 5 ml (or less) volumes to be fed through the bioreactors. Each PTHrP~1-36~ treatment was preceded by a 1-min flush, and the 2-h treatment was followed by 2 growth medium rinses and an overnight growth medium feed.

(PDF)

###### 

Click here for additional data file.

###### Complete list of wild-type trabecular osteoblast genes (total 188) whose expression is modified by exposure to 6 days of simulated microgravity (*Pthrp* ^+/+^ at 1g compared to *Pthrp* ^+/+^ at 0g).

**(A)** Genes (total 59) upregulated by 0g (6 days). Fold change \> 2.0, p \< 0.05. **(B)** Genes (total 129) downregulated by 0g (6 days). Fold change \< 0.5, p value\< 0.05. All probes: *Mus musculus*.

(PDF)

###### 

Click here for additional data file.

###### Complete list of trabecular osteoblasts genes (total 763) whose expression is modified by *Pthrp* gene ablation (*Pthrp* ^+/+^ at 1g compared to Pthrp^-/-^ at 1g).

**(A)** Genes (total 270) upregulated by *Pthrp* ablation at 1 g. Fold change \> 2.0, p \< 0.05. **(B)** Genes (total 493) downregulated by *Pthrp* ablation at 1g. Fold change \< 0.5, p value\< 0.05. All probes: *Mus musculus*.

(PDF)

###### 

Click here for additional data file.

###### Complete list of trabecular osteoblast genes whose expression is modified by intermittent PTHrP~1-36~ treatment (total 163 genes).

**(A)** Genes (total 102) upregulated by intermittent PTHrP~1-36~ treatment. Fold change \> 1.5, p \< 0.05. **(B)** Genes (total 61) downregulated by treatment. Fold changes \< 0.66, p \< 0.05.

(PDF)

###### 

Click here for additional data file.
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